The drug candidate acts by targeting tyrosine-protein kinase transmembrane receptor (ROR2). It is developed based on conditionally active biologics (CAB) ...
The drug candidate acts by targeting AXL receptor tyrosine kinase. The drug candidate is developed based on conditionally active biologics (CAB) platforms.
ADCT-601(BGB-601) is under development for the treatment of solid tumor, malignant fibrous histiocytoma. The drug candidate is an antibody drug conjugate ...